Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population

Adawi, Rana Moustafa Al; Jassim, Zainab; Elgaily, Dina; Abdelaziz, Hani; Sree, B. Vidya; Ibrahim, Mohamed Izham Mohamed

doi:10.1038/s41598-019-43052-6

Cited by 9 publications

(7 citation statements)

References 41 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 In a study by Moustafa et al Dapagliflozin significantly reduced the HbA1c level and FBG of type 2 diabetes patients as add-on therapy, regardless of the type of the co-administered OHA or insulin. 11 In a study by Strojek et al revealed that although incidents suggestive of genital infections were recorded more frequently in patients on dapagliflozin, it was usually well tolerated and dramatically improved HbA1c in patients with uncontrolled T2DM on sulphonyl urea monotherapy. 12 The results of current study also revealed that Dapagliflozin significantly improved the glycemic control of Type-2 diabetic patients when used in combination with standard therapy.…”

Section: Discussionmentioning

confidence: 99%

An observational study on dapagliflozin as an add-on therapy in type-2 diabetes mellitus patients in a tertiary care teaching hospital

Sahayaraj²,

Begum³

et al. 2023

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Diabetes mellitus is one of the prevalent morbid conditions all over the world and no exception for India. Day by day, increase in its prevalence is attributed to lifestyle derangements. To treat this condition many drugs and treatment modalities are developed. Dapagliflozin is an oral antidiabetic drug which acts by sodium-glucose cotransport-2 (SGLT-2) inhibition. Its effectiveness seen in type-2 diabetes mellitus makes it an option for Add-On therapy. Methods: This study is a retrospective observational study conducted at tertiary care hospital, GGH, Kurnool. The study proposal has been reviewed and approved by institutional ethics committee. All adult diabetic patients who were prescribed Dapagliflozin during the period of January 2021 to February 2022, total 45 were included in the study. FBG, HbA1c collected through hospital records from General Medicine and Endocrinology. Patients who stopped drug before 3 months period were excluded. Results: Administration of dapagliflozin as an add-on therapy was found 26.63% decrease in base line mean FBG 184 mg/dl to 135 mg/dl after 3mnoths which is significant (p=0.001). Mean HbA1c significantly reduced by 0.96 percentage point after 3 months (p=0.001). Dapagliflozin effectively reduced the FBG and HbA1c when used in combination with other OHAs or insulin within 3 months. Conclusions: Dapagliflozin as an add-on therapy significantly reduced the HbA1c level and fasting blood glucose of Type-2DM patients, in a 3-month treatment period. Due to the frequency of Genitourinary tract infections, caution is indicated while treating the patients.

show abstract

Section: Discussionmentioning

confidence: 99%

An observational study on dapagliflozin as an add-on therapy in type-2 diabetes mellitus patients in a tertiary care teaching hospital

Sahayaraj²,

Begum³

et al. 2023

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Fadini et al [15] reported similar results from the Italian observational study DARWIN-T2D; in >17,000 patients on dapagliflozin, there was a significant improvement in HbA1c levels (−0.7% [8 mmol/mol]) after an average of 5.5 months of treatment. Additionally, a more recent study assessed the effectiveness of dapagliflozin on T2DM patients and found that the administration of dapagliflozin as add-on therapy in combination with standard diabetic treatments decreased HbA1c levels significantly by 0.8% (9 mmol/mol) after 6 months and by 1.5% (16 mmol/mol) after 12 months [16]. Moreover, a randomized phase III trial conducted on treatment-naive Asian patients with T2DM demonstrated a −1.04% (11 mmol/mol) and 1.11% (12 mmol/mol) mean reduction in their HbA1c level after 24 weeks of treatment with 5 mg and 10 mg dapagliflozin, respectively [17].…”

Section: Discussion/conclusionmentioning

confidence: 99%

Real-World Assessment of Efficacy and Safety Parameters for Dapagliflozin in Management of Type 2 Diabetes Mellitus: REWARD Study

Hassoun¹,

Dhanwal²,

Nafach³

et al. 2022

Dubai Diabetes Endocrinol J

View full text Add to dashboard Cite

Introduction: While ample evidence on improved glycemic control, weight reduction, and lowered blood pressure (BP) with sodium-glucose cotransporter type 2 inhibitors (SGLT2is) exists, real-world data on the potential benefit of SGLT2i on the diabetic population in the Middle East are lacking. The aim of our study was to describe the glycemic control, changes in body weight, body mass index (BMI), lipid profile, and BPs in patients receiving dapagliflozin with other antidiabetic medication. Methods: The REWARD study was a multicenter, post-authorization, prospective, open-label, noninterventional, real-world, cohort study. We enrolled 511 adult, type 2 diabetes mellitus patients on antidiabetic medications. These patients were started on dapagliflozin and followed up for 1 year to assess changes in their clinical and laboratory outcomes. Results: The mean HbA1c decreased significantly from 8.5 ± 1.6% at baseline to 7.6 ± 1.3% after 12 months (p value <0.001), with an absolute change of 0.9%. Of the study population, 41.6% of patients reached an HbA1c level less than 7% (53 mmol/mol). The systolic pressure improved (mean change = −1.9 mm Hg, p value = 0.003), yet no change in the diastolic pressure was observed. Both body weight and BMI significantly decreased by 0.7 kg and 0.2 kg/m2, respectively (p value <0.001). About 84.5% of patients were on antidyslipidemic agents, while 57.4% were on antihypertensives. Approximately 83.6% of adverse events were mild. A total of 90 hypoglycemic episodes were reported; none were severe. Conclusion: In a real-world setting, dapagliflozin in combination with other antidiabetic medications exhibited significant improvement in glycemic control, weight, BMI, and systolic BP. Additionally, it demonstrated a well-tolerated safety profile.

show abstract

“…Our findings were corroborated by a more recent research which shown that Dapagliflozin, when administered in conjunction with other OHAs or insulin, successfully lowered HbA1c level and FBG within 6-12 months. 32 Multiple analyses of SGLT2 inhibitors have shown dapagliflozin to be effective. Studies [33][34] showed its efficacy as monotherapy for newly diagnosed T2-DM patients.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Dapagliflozin's Impact in Type 2 Diabetes Management as A Supplement to Metformin

Azhar¹,

Chaudhary²,

Jafri³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Objective: to analyzing the efficacy and safety of dapagliflozin in type 2 diabetics already taking metformin. Methodology: In this observational study at Madinah Teaching Hospital Faisalabad during July 2021 to October 2022, we enrolled 100 cases of either gender with 40-70 yrs, the impact of dapagliflozin 10 mg once daily in diabetics already taking metformin 1.5-2.5 g/day (DAPA + MET), and who had a follow-up visit at 6 months. The effectiveness was measured by the change in HbA1c at baseline at 12 months, as well as the change in BMI, creatinine and microalbumin levels at 6 months. Results: The effect and safety of Dapagliflozin was evaluated in terms of BMI before treatment 11.52+5.87 which reduced to 27.11+8.63 with significant difference, HbA1c(%) before treatment was 8.78+0.68 which reduced to 7.26+0.85 with a significant difference, sCr(μmol/L) was also reduced from baseline 147.76+6.92 to 142.76+6.41, Microalbumin(μg/mg) was 126.60+4.90 before treatment and 124.48+7.42 after treatment, showing a significant reduction. Conclusion: Patients with type 2 diabetes who received dapaglifozin as an add-on medication is found with a significant reduction in their HbA1c level as well as their FBG during a 6-month treatment period. Keywords: Type 2 diabetes

show abstract

Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population

Cited by 9 publications

References 41 publications

An observational study on dapagliflozin as an add-on therapy in type-2 diabetes mellitus patients in a tertiary care teaching hospital

An observational study on dapagliflozin as an add-on therapy in type-2 diabetes mellitus patients in a tertiary care teaching hospital

Real-World Assessment of Efficacy and Safety Parameters for Dapagliflozin in Management of Type 2 Diabetes Mellitus: REWARD Study

Evaluation of Dapagliflozin's Impact in Type 2 Diabetes Management as A Supplement to Metformin

Contact Info

Product

Resources

About